Streetbeat News

Analyst Ratings

HIMS

Spruce Point Capital Management has released a report expressing a strong sell research opinion on Hims & Hers Health, Inc.

Portfolio Pulse from Happy Mohamed

July 13, 2023 | 1:02 pm

CXM

Cantor Fitzgerald has maintained an Overweight rating on Sprinklr's stock and increased its price target from $17 to $20. This has led to Sprinklr shares trading higher.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 1:01 pm

VTLE

Analysts have provided mixed ratings for Vital Energy (NYSE:VTLE) within the last quarter, with 2 bullish, 1 somewhat bullish, 3 indifferent, and 2 somewhat bearish. The average 12-month price target for Vital Energy is $68.12, a decrease of 0.38% from the previous average price target of $68.38.

Portfolio Pulse from Benzinga Insights

July 13, 2023 | 1:01 pm

OPEN

In the last quarter, Opendoor Technologies (NASDAQ:OPEN) received 5 somewhat bullish and 2 somewhat bearish analyst ratings. The average 12-month price target for the company, according to 7 analysts, is $3.69, with a high of $8.00 and a low of $1.10. This average price target has increased by 4.83% over the past month.

Portfolio Pulse from Benzinga Insights

July 13, 2023 | 1:01 pm

PR

In the last quarter, Permian Resources (NYSE:PR) received various analyst ratings, with 2 bullish, 3 somewhat bullish, and 2 indifferent. Over the past 3 months, 7 analysts have offered 12-month price targets for the company, with an average price target of $14.29, a decrease of 3.12% from the previous average price target of $14.75.

Portfolio Pulse from Benzinga Insights

July 13, 2023 | 1:01 pm

GPN

In the last quarter, 19 analysts have provided ratings for Global Payments (NYSE:GPN) with an average 12-month price target of $136.79, a decrease of 1.21% from the previous average price target of $138.46. The ratings include 3 bullish, 11 somewhat bullish, and 5 indifferent.

Portfolio Pulse from Benzinga Insights

July 13, 2023 | 1:00 pm

IBP

Installed Building Prods (NYSE:IBP) has received one bullish and four indifferent analyst ratings in the last quarter. The average price target is $133.0, which is lower than the current price of $145.51, implying a downside. The average price target has increased by 13.87% over the past month.

Portfolio Pulse from Benzinga Insights

July 13, 2023 | 1:00 pm

RXRX

Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. The analysts have an average price target of $18.5 versus the current price of $12.08, implying an upside. This current average represents a 14.63% decrease from the previous average price target of $21.67.

Portfolio Pulse from Benzinga Insights

July 13, 2023 | 1:00 pm

ALNY

Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a $200 price target.

Portfolio Pulse from richadhand@benzinga.com

July 13, 2023 | 1:00 pm

CVNA

JP Morgan has downgraded Carvana's stock from Neutral to Underweight and set a price target of $10. This has led to a decrease in Carvana's share price.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 12:59 pm